Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 021829
Company: UCB INC
Company: UCB INC
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
NEUPRO | ROTIGOTINE | 2MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | Yes |
NEUPRO | ROTIGOTINE | 4MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
NEUPRO | ROTIGOTINE | 6MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
NEUPRO | ROTIGOTINE | 1MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
NEUPRO | ROTIGOTINE | 3MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
NEUPRO | ROTIGOTINE | 8MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription | None | Yes | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
05/09/2007 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD |
Label (PDF)
Letter (PDF) Patient Package Insert (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021829lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021829s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021829ppi.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021829s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
07/12/2021 | SUPPL-22 | Labeling-Patient Package Insert, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021829Orig1s021, s022ltr.pdf | |
07/12/2021 | SUPPL-21 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021829Orig1s021, s022ltr.pdf | |
04/03/2020 | SUPPL-19 | Labeling-Package Insert, Labeling-Patient Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s019lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021829Orig1s019ltr.pdf | |
04/24/2020 | SUPPL-17 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021829Orig1s017ltr.pdf | |
01/18/2019 | SUPPL-16 | Labeling-Patient Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021829s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021829Orig1s016ltr.pdf | |
11/29/2018 | SUPPL-15 | Labeling-Package Insert, Labeling-Patient Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021829s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/021829Orig1s015ltr.pdf | |
01/30/2017 | SUPPL-11 | Manufacturing (CMC) |
Label is not available on this site. |
||
06/03/2016 | SUPPL-10 | Manufacturing (CMC) |
Label is not available on this site. |
||
09/10/2015 | SUPPL-9 | Manufacturing (CMC) |
Label is not available on this site. |
||
02/26/2015 | SUPPL-7 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021829s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021829Orig1s007ltr.pdf | |
04/02/2012 | SUPPL-2 | Efficacy-New Indication |
Label (PDF)
Letter (PDF) Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/021829s001,s002ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021829Orig1s001s002.pdf | |
04/02/2012 | SUPPL-1 | Efficacy-New Indication |
Label (PDF)
Letter (PDF) Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/021829s001,s002ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021829Orig1s001s002.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
07/12/2021 | SUPPL-22 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf | |
07/12/2021 | SUPPL-22 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf | |
07/12/2021 | SUPPL-21 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021829s021s022lbl.pdf | |
04/24/2020 | SUPPL-17 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s017lbl.pdf | |
04/03/2020 | SUPPL-19 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s019lbl.pdf | |
04/03/2020 | SUPPL-19 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s019lbl.pdf | |
01/18/2019 | SUPPL-16 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021829s016lbl.pdf | |
11/29/2018 | SUPPL-15 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021829s015lbl.pdf | |
11/29/2018 | SUPPL-15 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021829s015lbl.pdf | |
02/26/2015 | SUPPL-7 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021829s007lbl.pdf | |
04/02/2012 | SUPPL-2 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf | |
04/02/2012 | SUPPL-1 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s001lbl.pdf | |
05/09/2007 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021829lbl.pdf |